Segment Reporting

Shire comprises one operating and reportable segment engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs. This is consistent with how the financial information is viewed for the purposes of evaluating performance, allocating resources, and planning and forecasting future periods and how the operations are managed by the Executive Committee (Shire’s chief operating decision maker).

This segment is supported by several key functions: a Pipeline Committee, an In-Line Committee, a Technical Operations group and a Corporate group. The Pipeline Committee consists of R&D and Corporate Development and is responsible for prioritizing the activities towards progressing and acquiring development programs across a variety of therapeutic areas. The Technical Operations group is responsible for the Company’s global supply chain. The In-line Committee focuses on commercializing marketed products and support of the development of the Company's pipeline candidates. The business is also supported by a simplified, centralized corporate function group. None of these functional groups meets all of the criteria to be considered an individual operating segment.

Geographic information

Revenues (based on the geographic location from which the sale originated):



	Years ended December 31,
(In millions)	2017		2016		2015
Ireland	$	55.5	$	41.6	$	14.1
United States	9,642.1		7,666.9		4,659.2
Rest of the world	5,463.0		3,688.1		1,743.4
Total revenues	$	15,160.6	$	11,396.6	$	6,416.7

Long-lived assets comprise all non-current assets, (excluding goodwill and intangible assets, deferred contingent consideration assets, deferred tax assets, investments and financial instruments) based on their relevant geographic location.



	Years ended December 31,
(In millions)	2017		2016
Ireland	$	94.0	$	41.2
United States	4,603.0		6,449.4
Austria	737.3		—
Rest of the world	1,314.3		84.0
Total	$	6,748.6	$	6,574.6

Material customers

In the periods set out below, certain customers accounted for greater than 10% of the Company’s Product sales:



	Years ended December 31,
	2017		2017	2016		2016	2015		2015
(in millions, except %)			% Product sales			% Product sales			% Product sales
AmerisourceBergen Corp	$	1,408.1	10	$	1,695.3	16	$	1,048.3	17
McKesson Corp.	1,333.1		9	1,336.7		12	1,044.1		17
Cardinal Health Inc.	1,079.2		7	1,052.2		10	796.9		13

Amounts outstanding in respect of these material customers were as follows:



	December 31,
(In millions)	2017		2016
AmerisourceBergen Corp	$	469.9	$	427.2
McKesson Corp.	512.4		312.9
Cardinal Health Inc.	325.3		278.4

In the periods set out below, Revenues by franchise were as follows. In 2017, Immunology includes HAE from Genetic Diseases; prior year amounts have been reclassified to conform with current year presentation.



	Years ended December 31,
(In millions)	2017		2016		2015
Product sales by franchise
IMMUNOGLOBULIN THERAPIES	$	2,236.6	$	1,143.9	$	—
HEREDITARY ANGIOEDEMA	1,429.6		1,310.9		1,062.7
BIO THERAPEUTICS	704.1		372.2		—
Immunology	4,370.3		2,827.0		1,062.7
HEMOPHILIA	2,957.3		1,789.0		—
INHIBITOR THERAPIES	828.3		451.8		—
Hematology	3,785.6		2,240.8		—
VYVANSE	2,161.1		2,013.9		1,722.2
ADDERALL XR	348.0		363.8		362.8
MYDAYIS	21.6		—		—
Other Neuroscience	133.4		112.8		115.4
Neuroscience	2,664.1		2,490.5		2,200.4
LIALDA/MEZAVANT	569.4		792.1		684.4
GATTEX/REVESTIVE	335.5		219.4		141.7
PENTASA	313.2		309.4		305.8
NATPARA/NATPAR	147.4		85.3		24.4
Other Internal Medicine	304.8		349.3		344.3
Internal Medicine	1,670.3		1,755.5		1,500.6
ELAPRASE	615.7		589.0		552.6
REPLAGAL	472.1		452.4		441.2
VPRIV	349.9		345.7		342.4
Genetic Diseases	1,437.7		1,387.1		1,336.2
Oncology	261.7		130.5		—
Ophthalmics	259.2		54.4		—
Total Product sales	14,448.9		10,885.8		6,099.9
Royalties and other revenues
Royalties	448.4		382.6		300.5
Other revenues	263.3		128.2		16.3
Total royalties and other revenues	711.7		510.8		316.8
Total revenues	$	15,160.6	$	11,396.6	$	6,416.7